Loading...
ADOC
XPAR
Market cap79mUSD
Nov 20, Last price  
3.29EUR
1D
-6.80%
1Q
-21.10%
Jan 2017
-94.61%
IPO
-78.27%
Name

Adocia SA

Chart & performance

D1W1MN
XPAR:ADOC chart
P/E
—
P/S
49.09
EPS
—
Vol. 1Y
76.31%
Shs. 5Y
22.97%
Rev. 5Y
11.89%
Div Yld LY
—
Div Yld TTM
—
Revenues
1m
-84.17%
111,0001,551,0003,996,0005,589,000704,00036,936,00022,488,00019,469,00047,389,0002,143,000841,0001,444,00011,447,0002,150,0009,320,0001,475,000
Net income
-17m
L+78.00%
-4,731,000-6,454,000-5,995,000-4,293,000-20,715,00012,553,000-7,892,000-8,551,0007,615,000-18,603,000-23,324,000-22,754,000-6,901,000-21,162,000-9,321,000-16,591,000
CFO
-7m
L-58.17%
-4,956,000-6,217,000919,000-10,796,00030,561,000-6,216,000-13,138,000-22,227,0006,313,000-9,655,000-21,854,000-19,234,000-14,995,000-4,950,000-15,612,000-6,530,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Adocia S.A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company leverages its unique BioChaperone technological platform, specifically designed to boost the performance of these therapeutic proteins. Its robust clinical pipeline showcases several advanced insulin formulations, including BioChaperone Lispro U100 and U200, which are ultra-rapid-acting versions of insulin lispro. Other key candidates are BioChaperone Combo, a blend of long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous human glucagon formulation for managing hypoglycemia. M1Pram, a derivative combining insulin glargine and pramlintide, is also under clinical investigation. In its earlier preclinical development phases, Adocia is advancing bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose pairing of insulin glargine with a GLP-1 receptor analogue. The preclinical portfolio also extends to multihormonal therapies for obesity, featuring BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple combination of pramlintide, glucagon, and exenatide. Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. to facilitate the development and commercialization of BioChaperone Lispro and BioChaperone Combo in China, as well as selected markets in Asia and the Middle East. The company was founded in 2005 and is headquartered in Lyon, France.

Key people

Gerard Soula
Executive Chairman of the Board · since 2023
Mathieu-William Gilbert
Chief Financial Officer, Chief Operating Officer · since 2024
Olivier Soula
Chief Executive Officer, R&D Director, Vice President, Member of the Executive Committee, Director · since 2023
Independent Director · since 2021
Mads Dall
Independent Director · since 2022
Valerie Moumdjian
Independent Director · since 2024
IPO date
Feb 20, 2012
Employees
96
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
115 AVENUE LACASSAGNE
LYON 69003
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT